Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agilent Announces Global Distribution Agreement with Cartagenia for CNV Analysis

Published: Friday, May 30, 2014
Last Updated: Friday, May 30, 2014
Bookmark and Share
To assist cytogenetic labs in the clinical interpretation of microarray data.

Agilent Technologies Inc. has announced an agreement for global distribution of Cartagenia's cloud-based software for copy number variation (CNV) analysis. This agreement will enable Agilent to sell usage-priced annual licenses for Cartagenia's Bench Lab CNV module to small and medium-sized cytogenetic laboratories.

The use-based licenses allow labs with limited budgets and little or no bioinformatics resources to gain access to a powerful interpretation support module to draft clinical grade reports.

"Cartagenia is pleased to work with Agilent on this distribution agreement of our Bench Lab CNV module," said Herman Verrelst, chief executive officer, Cartagenia. "Patient-centric interpretation of microarray data can be greatly facilitated by adopting automated data analysis pipelines and workflows, increasing lab efficiency."

"With expanded distribution capabilities, we can now reach small- to medium-sized labs more efficiently and provide them with our data analysis platform," Verrelst added. "The CNV module is a proven platform, offers standardized workflows, and automated SOPs for fast turnaround times. Since it is a cloud-based platform, it allows for rapid installation, integration with legacy data, and provides labs with greater access to our product without adding bioinformatics resources."

Cartagenia supplies interpretation support software, database systems and related services to genetic labs and clinicians, enabling them to perform clinically relevant analysis of genetic findings quickly and efficiently.

The Cartagenia Bench CNV platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab CNV addresses the specific needs of genetic diagnostic labs and clinicians.

"Agilent is the first worldwide reseller to offer the Cartagenia Bench Lab CNV, and we are excited to provide this solution," said Jacob Thaysen, Agilent's vice president and general manager, Diagnostics and Genomics Group. "Labs with minimal software budget and resources can now afford to implement proven, standardized processes to analyze, interpret, and report their CGH data and generate precise draft lab reports with minimal disruption to their analysis workflow and staff."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies Launches New Products for Analyzing Biotherapeutics
Expanded AdvanceBio portfolio enables scientists to speed research and lower costs.
Thursday, June 25, 2015
Agilent Announces New CEO Mike McMullen
McMullen elected as chief executive officer by Company’s board of directors.
Thursday, March 19, 2015
Agilent’s Microarray Scanner Approved for In Vitro Diagnostics in China
Regulators approve SureScan Dx as medical device.
Wednesday, January 28, 2015
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent Appoints Senior VP and President of Life Sciences and Diagnostics Group
Fred Strohmeier, has been named senior vice president, Agilent, and president of Agilent's Life Sciences and Diagnostics Group (LDG), effective immediately.
Wednesday, December 18, 2013
Dako Publishes Sixth Edition of Immunohistochemistry Guidebook
Reference book used by pathology laboratories worldwide.
Monday, December 16, 2013
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent Technologies to Separate into Two Public Companies
Life sciences, diagnostics and applied markets (LDA) that will retain the Agilent name, and the other company will be comprised of Agilent's electronic measurement (EM) products.
Monday, September 23, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.
Monday, April 08, 2013
Dako to Collaborate with Pfizer
Collaboration agreement in the field of companion diagnostics.
Monday, February 18, 2013
Dako Receives FDA Approval for Fast, Accurate, Nontoxic FISH Assay for Cancer Diagnostics
Dako, an Agilent Technologies Company, has introduced IQISH technology in the United States.
Monday, February 18, 2013
Agilent Technologies Microarrays Used in Groundbreaking Prenatal Research Study
Agilent Technologies Inc. announced its microarrays were used in a landmark prenatal research study published on Thursday in the New England Journal of Medicine.
Monday, December 10, 2012
Agilent Technologies Appoints Ron Nersesian President and COO
The company's board of directors has appointed Ron Nersesian Agilent president and chief operating officer, effective immediately.
Thursday, November 15, 2012
Agilent Technologies Names Diagnostics and Genomics Group President
Lars Holmkvist appointed as president of company’s Diagnostics and Genomics Group (DGG) and a senior vice president of Agilent, effective immediately.
Friday, September 14, 2012
Scientific News
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos